Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC-Reference-Cited by-同舟云学术

Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC

Published:2019-04 Issue: Volume:30 Page:i38
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mok T.S.K,Wu Y.-L.,Kudaba I.,Kowalski D.M.,Cho B.C.,Turna H.Z.,de Castro G.,Srimuninnimit V.,Laktionov K.K.,Bondarenko I.,Kubota K.,Caglevic C.,Karaszewska B.,Dang T.,Yin L.,Penrod J.,Lopes G.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/Supplement_2/mdz063/28355624/mdz063.pdf

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. METTL3 inhibition-activated cGAS/STING axis enhances immunotherapy and PARP inhibitor sensitivity of lung carcinoma;2024-09-06

2. Real-world clinical and economic outcomes for patients with advanced non–small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy;Journal of Managed Care & Specialty Pharmacy;2024-07

3. Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis;Frontiers in Oncology;2023-02-07

4. Real-world assessment of attenuated dosing anti-PD1 therapy as an alternative dosing strategy in a high-income country (as defined by World Bank);Frontiers in Oncology;2022-11-17

5. Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis;Lung Cancer;2022-08